2017年全球传染病热点回顾  

Hot spots review of global infectious diseases in 2017

作　　者：李硕[1] 张云辉[1] 王永怡[1] 李军[1] 胡玫[1] 赵雅琳[1] 闫晶晶[1] 孙志杰[1] 揣征然 姬军生[2] 

机构地区：[1]《传染病信息》杂志社,北京100039 [2]解放军第三0二医院

出　　处：《传染病信息》2018年第1期5-10,共6页Infectious Disease Information

摘　　要：2017年全球疫情局势相对较平静,但也有一些事件影响比较大:因战乱导致发生在也门和非洲局部地区的霍乱疫情造成上百万病例,数千人死亡;马达加斯加暴发鼠疫,病例数超过2600例;年末,北半球流感活动强度达近10年来最高强度。2017年,一些重要疫苗研发和使用有较大进展,寨卡病毒病疫苗、艾滋病疫苗研发有多项进步;中国研发重组埃博拉病毒病疫苗全球首个获批并上市;宫颈癌疫苗亦在中国内地上市。二合一抗HIV药Juluca问世,将大大简化艾滋病抗病毒治疗。多款治疗丙型肝炎的直接抗病毒药物集中登录中国内地。本文仅对与临床相关的若干事件作回顾。In 2017, the global epidemic situation is relatively calm, accompanying with several influential events, such as the epidemic of cholera due to the war in Yemen and parts of Africa has affected millions of cases and caused thousands of deaths; the outbreak of plague in Madagascar covers 2600 cases; at the end of 2017, the intensity of influenza prevalent in the northern hemisphere reaches the peak within recent 10 years. In 2017, significant progress has been made in the development, research and utilization of some key vaccines. The research and development of Zika vaccine and AIDS vaccine have achieved many improvements. A Chinese vaccine targeting recombinant Ebola virus obtains the first clinical approval and is applied in the world. Cervical cancer vaccines appears on the market in China's Mainland. The advent of two-in-one anti-HIV drug Juluca will greatly simplify HIV antiviral treatment. A variety of direct antiviral drugs to treat hepatitis C focus on the market in China's Mainland. This article aims to reviews a few clinically relevant events.

关 键 词：传染病 疫情 事件 回顾 

分 类 号：R51[医药卫生—内科学]